 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...3233343536373839404142...235236» |
- | 5-fluorouracil / Generic mfg.
Journal, HEOR, Real-world evidence, Real-world: Cost-Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand. (Pubmed Central) - Oct 28, 2023
It is cost-effective compared with 5-FU/LV then FOLFOX. However, policymakers should consider the relatively high budgetary burden of the CAPOX then FOLFIRI regimen.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. (Pubmed Central) - Oct 28, 2023
In total, 206 consecutive patients were included in the study, whereof 142 patients (68.9%) received palliative chemotherapy (gemcitabine/nab-paclitaxel 33.8%; FOLFIRINOX 35.9%; gemcitabine 30.3%) while the remainder were treated with best supportive and integrative care...A total of 107/142 patients (86.3%) died during the observation period, whereby survival times differed significantly depending on the additional use of integrative mistletoe or hyperthermia: chemotherapy alone 8.6 months (95% CI 4.7-15.4), chemotherapy and only mistletoe therapy 11.2 months (95% CI 7.1-14.2), or a combination of chemotherapy with mistletoe and hyperthermia 18.9 months (95% CI 15.2-24.5). While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia.
- ||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Oct 27, 2023
P1/2, N=410, Active, not recruiting, Sponsor: Hoffmann-La Roche
While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia. Recruiting --> Active, not recruiting
- || Lumakras (sotorasib) / Amgen
Trial completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 27, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial completion date: Jul 2027 --> Oct 2027
- ||||||| Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial completion, Combination therapy, Metastases: AGENT: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 26, 2023
P3, N=490, Completed, Sponsor: Isofol Medical AB
Trial completion date: Jul 2027 --> Oct 2027 Active, not recruiting --> Completed
- || Onivyde (nanoliposomal irinotecan) / Ipsen
Trial completion date, Trial primary completion date: SIRACUSA: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (clinicaltrials.gov) - Oct 26, 2023
P1, N=122, Recruiting, Sponsor: Ipsen
Active, not recruiting --> Completed Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024
- | leucovorin calcium / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Oct 25, 2023
P2, N=134, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024 Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
- | leucovorin calcium / Generic mfg.
Enrollment open: Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium (clinicaltrials.gov) - Oct 25, 2023
P2, N=80, Recruiting, Sponsor: Southwest Autism Research & Resource Center
Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025 Active, not recruiting --> Recruiting
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening. (Pubmed Central) - Oct 25, 2023
Active, not recruiting --> Recruiting CSF3R participates in the occurrence and development of OS bone destruction by regulating the inflammatory response of osteoblasts and osteoclasts and can affect the survival prognosis of OS patients.
- | New P2 trial: Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy (clinicaltrials.gov) - Oct 25, 2023
P2, N=53, Not yet recruiting, Sponsor: Sun Yat-sen University
- ||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Adverse events, Metastases: The Impact of Omitting 5-FU Bolus From mFOLFOX6 Chemotherapy Regimen on Hematological Adverse Events Among Patients With Metastatic Colorectal Cancer. (Pubmed Central) - Oct 24, 2023
The 5-fluorouracil (5-FU) bolus is often omitted from the regimen to reduce the risk of hematological adverse events (AEs) in patients with poor performance status...mCRC patients who were treated with bolus 5-FU had lower ANC. The 5-FU bolus omission from the mFOLFOX6 regimen may be required in patients with a high risk of neutropenia.
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 24, 2023
P3, N=847, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The 5-FU bolus omission from the mFOLFOX6 regimen may be required in patients with a high risk of neutropenia. Trial completion date: Sep 2023 --> Sep 2024
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 24, 2023
P2, N=39, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Sep 2023 --> Sep 2024 Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Oct 24, 2023
P1/2, N=383, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Trial completion date: Jun 2023 --> Sep 2024
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (clinicaltrials.gov) - Oct 23, 2023
P3, N=202, Active, not recruiting, Sponsor: GCS IHFB Cognacq-Jay
Trial completion date: Jun 2023 --> Sep 2024 Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2023
- | Avastin (bevacizumab) / Roche
Journal: FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy. (Pubmed Central) - Oct 23, 2023
ATL is mostly reversible, but the progression of neurologic symptoms was also reported. The diagnosis and cessation of the responsible agent are important in management.
- | Journal: Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy. (Pubmed Central) - Oct 23, 2023
This is the first report that posterior reversible encephalopathy syndrome is caused by a thrombocytopenia regimen, and our case highlights the pathogenic role of a thrombocytopenia regimen in posterior reversible encephalopathy syndrome. However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, BRCA Biomarker, Circulating tumor DNA, Epigenetic controller: Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection. (Pubmed Central) - Oct 23, 2023
P2
However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study. Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.
- || AB598 / Arcus Biosci
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov) - Oct 23, 2023
P1, N=81, Recruiting, Sponsor: Arcus Biosciences, Inc.
Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker. Trial completion date: Nov 2025 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2025
- | oxaliplatin / Generic mfg.
Journal, BRCA Biomarker, Metastases: A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer. (Pubmed Central) - Oct 23, 2023
After 12 cycles of FOLFIRINOX, liver metastases disappeared and the patient underwent pancreaticoduodenectomy...To the best of our knowledge, the presented case is the longest recurrence-free survival after platinum-based therapy in metastatic pancreatic cancer with BRCA mutation. Our case emphasizes that investigating BRCA gene mutations at the time of diagnosis can be life-saving in these patients.
- |||||||||| osemitamab (TST001) / Transcenta
New P3 trial: Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma (clinicaltrials.gov) - Oct 23, 2023
P3, N=950, Not yet recruiting, Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
- | Imfinzi (durvalumab) / AstraZeneca, Neulasta (pegfilgrastim) / Roche
New P2 trial: NEO-IMPACT: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer (clinicaltrials.gov) - Oct 23, 2023
P2, N=20, Recruiting, Sponsor: Australasian Gastro-Intestinal Trials Group
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Review, Journal, Checkpoint inhibition, Metastases: Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis. (Pubmed Central) - Oct 22, 2023
Our case emphasizes that investigating BRCA gene mutations at the time of diagnosis can be life-saving in these patients. The triple combination therapy of HAIC-FO plus TKI and ICIs showed promising efficacy and safety in patients with advanced HCC.
- || Review, Journal: Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. (Pubmed Central) - Oct 22, 2023
Here, we review several oncomiRs and TsmiRs involved in chemoresistance to gemcitabine and FOLFIRINOX in PDAC and highlighted successful/effective miRNA-based therapy approaches in vivo. Integrating miRNAs in PDAC treatment represents a promising therapeutic avenue that can be used as guidance for personalized medicine for PDAC patients.
- || 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
P1 data, Journal: Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases. (Pubmed Central) - Oct 22, 2023
As oncological outcomes were promising, intraperitoneal administration of irinotecan may be a good alternative to other, more invasive and costly treatment options. A phase II study is currently accruing.
- || P2 data, Journal, Metastases: A Multi-Institutional Phase II Trial of Ablative 5-Fraction Stereotactic MR-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. (Pubmed Central) - Oct 22, 2023
Although it is unclear whether SMART contributed to postoperative toxicity, we recommend caution when pursuing surgery, especially with vascular resection after SMART. Additional follow-up is ongoing to evaluate late toxicity, quality of life, and long-term efficacy.
- | 5-fluorouracil / Generic mfg.
Journal: Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. (Pubmed Central) - Oct 21, 2023
Therefore, an expert consensus conference was held on March 2023 in Guangzhou, China to review current practices regarding HAIC treatment in patients with HCC and develop widely accepted statements and recommendations. In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management.
- || Ampligen (rintatolimod) / AIM ImmunoTech
Trial completion date, Trial primary completion date: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Oct 19, 2023
P2, N=90, Recruiting, Sponsor: AIM ImmunoTech Inc.
In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management. Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Nov 2026 --> Jun 2027
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Oct 18, 2023
P2, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Nov 2026 --> Jun 2027 Trial completion date: Jun 2024 --> Sep 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2024 --> Sep 2024 Trial completion date: Apr 2024 --> Sep 2024
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P2, N=80, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Apr 2024 --> Sep 2024 Recruiting --> Active, not recruiting
- Trial termination, Metastases: Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (clinicaltrials.gov) - Oct 18, 2023
P2, N=1, Terminated, Sponsor: HonorHealth Research Institute
Recruiting --> Active, not recruiting Completed --> Terminated; Study was closed due to low subject enrollment at site.
- | Avastin (bevacizumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (clinicaltrials.gov) - Oct 17, 2023
P1/2, N=30, Active, not recruiting, Sponsor: Centre Georges Francois Leclerc
Completed --> Terminated; Study was closed due to low subject enrollment at site. Recruiting --> Active, not recruiting | N=55 --> 30 | Trial completion date: Jan 2023 --> Nov 2024 | Trial primary completion date: Jan 2023 --> Nov 2024
- | Enrollment change, Trial completion date, Trial primary completion date: PANCREAS: PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples (clinicaltrials.gov) - Oct 17, 2023
P2, N=87, Recruiting, Sponsor: Medical College of Wisconsin
Recruiting --> Active, not recruiting | N=55 --> 30 | Trial completion date: Jan 2023 --> Nov 2024 | Trial primary completion date: Jan 2023 --> Nov 2024 N=41 --> 87 | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Metastases: NEOPAN: A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma (clinicaltrials.gov) - Oct 16, 2023
P3, N=171, Active, not recruiting, Sponsor: UNICANCER
N=41 --> 87 | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2026 Trial completion date: Jan 2027 --> Nov 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 16, 2023
P2, N=39, Completed, Sponsor: Al B. Benson, III, MD
Trial completion date: Jan 2027 --> Nov 2023 Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- || Review, Journal: Exosomes: Emerging Modulators of Pancreatic Cancer Drug Resistance. (Pubmed Central) - Oct 14, 2023
The most used therapy is gemcitabine, alone or in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), and the multidrug FOLFIRINOX...This review illustrates the role of exosomes in PaC drug resistance. This manuscript first provides an overview of the pharmacological approaches used in PaC and, in the last part, focuses on the mechanisms exploited by the exosomes released by cancer cells to induce drug resistance.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date: KEYNOTE-585 China Extension study: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (clinicaltrials.gov) - Oct 13, 2023
P3, N=120, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
This manuscript first provides an overview of the pharmacological approaches used in PaC and, in the last part, focuses on the mechanisms exploited by the exosomes released by cancer cells to induce drug resistance. Trial completion date: Jul 2026 --> Feb 2024 | Trial primary completion date: Jul 2026 --> Feb 2024
- |||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion, Metastases: AtezoTRIBE: FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Oct 12, 2023
P2, N=218, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial completion date: Jul 2026 --> Feb 2024 | Trial primary completion date: Jul 2026 --> Feb 2024 Active, not recruiting --> Completed
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Trial completion date, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 12, 2023
P2, N=363, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023
- | leucovorin calcium / Generic mfg.
New P2 trial: PHOX: Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 12, 2023
P2, N=99, Not yet recruiting, Sponsor: Mayo Clinic
- |||||||||| trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
New P2/3 trial, New P2b trial, Combination therapy, Metastases: STOP-PC: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 12, 2023
P2b, N=468, Not yet recruiting, Sponsor: Oncotelic Inc.
- | Herzuma (trastuzumab-pkrb) / Nippon Kayaku, Mundipharma, Celltrion, Teva
Trial completion, Trial completion date, Trial primary completion date, Pan tumor: KCSG-HB19-14: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy (clinicaltrials.gov) - Oct 11, 2023
P2, N=36, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023 Recruiting --> Completed | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Jun 2023
- | Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. (Pubmed Central) - Oct 11, 2023
This study investigated the cost-effectiveness and quality of life (QoL) within 1 year of receiving mFOLOFX6 with or without a targeted drug (bevacizumab or ramucirumab) as second-line treatment among patients with metastatic colorectal cancer (mCRC) following the failure of FOLFIRI + bevacizumab as first-line treatment...Addition of a targeted drug to the second-line mFOLOFX6 regimen not only improved the patients' QoL but was also more cost effective when the willingness-to-pay threshold was set at US$33,004 (the per capita gross domestic product of Taiwan). These patients should be reimbursed for these targeted agents by the National Health Insurance scheme in Taiwan.
- || ivaltinostat IV (CG-745) / CG Invites
Trial primary completion date, Metastases: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 10, 2023
P1b/2, N=70, Recruiting, Sponsor: CG Pharmaceuticals, Inc
These patients should be reimbursed for these targeted agents by the National Health Insurance scheme in Taiwan. Trial primary completion date: Sep 2023 --> Feb 2025
- | 5-fluorouracil / Generic mfg.
Journal, IO biomarker: A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy. (Pubmed Central) - Oct 9, 2023
The patient received two cycles of modified FOLFIRINOX plus immune checkpoint inhibitor (Penpulimab)...Three cycles of combined therapy were adopted after surgery followed by maintained therapy with anlotinib plus Penpulimab. There was no evidence of tumor recurrence 19 months since diagnosis.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_905;
In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%...In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT...Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
- A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_770;
A total of 211 events are required in the entire study for this analysis to be feasible with a hazard ratio of 0.68. We have assumed a uniform accrual period of 38 months and further 16 months of follow-up.
- Kaitanni (cadonilimab) / Akesobio
Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS?5 (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_757;
Results From Aug 2022 to Aug 2023, 22 pts were enrolled, of which 14 (63.6%) received cadonilimab (10mg/kg, q3w) plus SOX, 4 (18.2%) received cadonilimab (10mg/kg, q3w) plus XELOX and 3 (13.6%) received cadonilimab (6mg/kg, q2w) plus FOLFOX...Conclusions This real-world analysis further confirmed the promising efficacy and safety of cadonilimab plus chemotherapy as first-line treatment in advanced G/GEJ cancer pts with PD-L1 CPS?5. Further exploration is ongoing and the updated analysis in a larger population is expected in the future.